Active Ingredient History

  • Now
Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by AstraZeneca. It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma. It has been given conditional approval for these indication in China.   Wikipedia

  • SMILES: C[C@@H](c1ccc2nccn2c1)n3nnc4ncc(nc34)c5cnn(C)c5
  • Mol. Mass: 345.37
  • ALogP: 1.88
  • ChEMBL Molecule:
More Chemistry


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue